Cite
HARVARD Citation
Plesner, T. et al. (2019). Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study. British journal of haematology. pp. e35-e39. [Online].